Oxurion (TBGNF) News Today $0.17 0.00 (0.00%) As of 09/19/2023 Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period OXURION: Oxurion Receives Amended Transparency Notification from Atlas Special Opportunities LLCJanuary 14 at 7:04 PM | finanznachrichten.deOxurion Receives Amended Transparency Notification from Atlas Special Opportunities LLCJanuary 14 at 7:04 PM | actusnews.comOxurion Updates on Atlas Shareholding ChangesJanuary 14 at 12:40 PM | tipranks.comOxurion Expands Capital to Enhance Ophthalmic InnovationsJanuary 13 at 12:52 PM | tipranks.comOxurion Receives Significant Shareholding Notification from AtlasJanuary 6, 2025 | tipranks.comOxurion NV Expands Capital for Innovative Eye CareJanuary 3, 2025 | tipranks.comOxurion NV Delays Strategic Transaction SigningDecember 31, 2024 | tipranks.comFrench Authorities Approve Oxurion's Strategic Transaction Under Specific ConditionsDecember 20, 2024 | actusnews.comOxurion NV Gains Approval for Strategic TransactionDecember 19, 2024 | tipranks.comOxurion’s Shareholder Atlas Reduces StakeDecember 12, 2024 | tipranks.comOxurion Sees Stake Reduction by Atlas Special OpportunitiesDecember 4, 2024 | tipranks.comOxurion announces that its potential acquisition is subject to foreign investment controlNovember 29, 2024 | actusnews.comOxurion Awaits French Approval for AcquisitionNovember 28, 2024 | tipranks.comOXURION: Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLCOctober 3, 2024 | finanznachrichten.deOXURION: Oxurion Publishes First Half 2024 ResultsOctober 1, 2024 | finanznachrichten.deOxurion Publishes First Half 2024 ResultsOctober 1, 2024 | actusnews.comOXURION: Oxurion: Progress in the Fight Against Age-Related Macular DegenerationSeptember 14, 2024 | finanznachrichten.deOXURION: Oxurion: Progress in the Fight Against AMDSeptember 12, 2024 | finanznachrichten.deOxurion: Progress in the Fight Against AMDSeptember 12, 2024 | actusnews.comOXURION: Oxurion Receives Transparency Notification from Atlas Special Opportunities LLCSeptember 4, 2024 | finanznachrichten.deOxurion Share ConsolidationJuly 25, 2024 | uk.finance.yahoo.comOxurion NV: Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMDMay 6, 2024 | finanznachrichten.deOxurion NV: Oxurion Receives EUR 450,000 in the framework of the Atlas Funding Program: Eleventh tranche fully issued and paid-upApril 10, 2024 | finanznachrichten.deOxurion Receives EUR 450,000 in the framework of the Atlas Funding Program : Eleventh tranche fully issued and paid-upApril 10, 2024 | markets.businessinsider.comOxurion NV: Postponement Annual Shareholders Meeting - Amendment financial calendarApril 5, 2024 | finanznachrichten.deOxurion NV: Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas - Amended versionMarch 27, 2024 | finanznachrichten.deOxurion Receives EUR 300,000 in the framework of the Atlas Funding Program Tenth tranche fully issued and paid-upMarch 5, 2024 | finance.yahoo.comOxurion NV: Oxurion Announces New Strategic Orientation to De-risk and DiversifyJanuary 22, 2024 | finanznachrichten.deOxurion Avoids Bankruptcy, Announces Board and Management Changes and Enters into Binding Letter of Intent with its Main Creditor AtlasDecember 28, 2023 | finance.yahoo.comOxurion Discloses Topline Data from KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular EdemaNovember 20, 2023 | uk.finance.yahoo.comOxurion NV OXURNovember 14, 2023 | morningstar.comOxurion Announces Key Amendments to Atlas and Kreos/Pontifax Agreements Enabling KALAHARI Trial to Progress to Topline Results in 2023October 1, 2023 | uk.finance.yahoo.comOxurion Publishes First Half 2023 ResultsSeptember 29, 2023 | uk.finance.yahoo.comOxurion Receives First EUR 1 Million under Amended Atlas Funding ProgramSeptember 19, 2023 | finance.yahoo.comOxurion unlocks $1m from Atlas for diabetic macular oedema therapyAugust 11, 2023 | msn.comOxurion NV: Oxurion Receives Funding of EUR One Million under Atlas Special Opportunities LLC (Atlas) Funding ProgramAugust 11, 2023 | finanznachrichten.deOxurion NV (TG4.BE)August 8, 2023 | uk.finance.yahoo.comOxurion NV: Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLJuly 27, 2023 | finanznachrichten.deOxurion Receives Transparency Notifications from Atlas Special Opportunities LLJuly 27, 2023 | finance.yahoo.comOxurion NV: Oxurion Receives Upfront Payment of $400,000 Following Oncurious Asset License by VIBJuly 25, 2023 | finanznachrichten.deOxurion Receives Upfront Payment of $400,000 Following Oncurious Asset License by VIBJuly 25, 2023 | finance.yahoo.comOxurion Issues EUR 1.0 million in Bonds for Tranche 3 of the Funding Program with Atlas Special Opportunities LLCJune 15, 2023 | finance.yahoo.comOxurion to Participate in Upcoming ConferencesJune 1, 2023 | finance.yahoo.comOxurion NV: Oxurion Reaches Enrollment Target in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular EdemaMay 25, 2023 | finanznachrichten.deOxurion Issues EUR 2.0 million in Bonds for Tranche 2 of the Funding Program with Atlas Special Opportunities LLCMay 22, 2023 | finance.yahoo.comOxurion NV: Oxurion Issues EUR 2.0 million in Bonds for Tranche 1 (B) of the Funding Program with Atlas Special Opportunities LLCApril 27, 2023 | finanznachrichten.deOxurion Issues EUR 2.0 million in Bonds for Tranche 1 (B) of the Funding Program with Atlas Special Opportunities LLCApril 27, 2023 | finance.yahoo.comOxurion Receives Transparency Notifications from Atlas Special Opportunities LLCApril 24, 2023 | finance.yahoo.comOxurion NV: Oxurion Receives Transparency Notification from Atlas Special Opportunities LLCApril 14, 2023 | finanznachrichten.deOxurion Receives Transparency Notification from Atlas Special Opportunities LLCApril 14, 2023 | technews.tmcnet.com Get Oxurion News Delivered to You Automatically Sign up to receive the latest news and ratings for TBGNF and its competitors with MarketBeat's FREE daily newsletter. Email Address TBGNF Media Mentions By Week TBGNF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TBGNF News Sentiment▼0.870.78▲Average Medical News Sentiment TBGNF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TBGNF Articles This Week▼40▲TBGNF Articles Average Week Get Oxurion News Delivered to You Automatically Sign up to receive the latest news and ratings for TBGNF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Algernon Pharmaceuticals News ALK-Abelló A/S News Alpha Tau Medical News Apollomics News Arno Therapeutics News Ascentage Pharma Group International News Ascletis Pharma News Avacta Group News Awakn Life Sciences News AXIM Biotechnologies News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:TBGNF) was last updated on 1/15/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oxurion NV Please log in to your account or sign up in order to add this asset to your watchlist. Share Oxurion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
